The research reveals how specific biomarkers in SCLC tumors could open new opportunities for more personalized and targeted therapies for these patients. SCLC accounts for about 15% of all lung ...

Panelists discuss how tarlatamab, a bispecific T-cell engager therapy, received accelerated approval for extensive-stage small cell lung cancer (SCLC) in May 2024, examining its mechanism of ...

Biomarker testing in SCLC is essential for personalizing treatment, though less established than in non-small cell lung cancer. Testing is usually incorporated at diagnosis or during disease ...